RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $45

Benzinga · 21h ago
RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $48 to $45.